General Information of the Drug (ID: M6APDG00507)
Name
Gly-Hyp-Glu
Synonyms
Gly-Hyp-Glu; CHEMBL380624; SCHEMBL2084290; MPZCPLJCORMPJI-CSMHCCOUSA-N; glycyl-l-hydroxyprolyl-l-glutamic acid; Glycyl-trans-4-hydroxy-L-prolyl-L-glutamic acid
    Click to Show/Hide
Status
Investigative
Structure
Formula
C12H19N3O7
InChI
1S/C12H19N3O7/c13-4-9(17)15-5-6(16)3-8(15)11(20)14-7(12(21)22)1-2-10(18)19/h6-8,16H,1-5,13H2,(H,14,20)(H,18,19)(H,21,22)/t6-,7+,8+/m1/s1
InChIKey
MPZCPLJCORMPJI-CSMHCCOUSA-N
PubChem CID
11902976
TTD Drug ID
D0P3MF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glutamate receptor ionotropic NMDA 1 (NMDAR1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Glutamate receptor ionotropic NMDA 1 (NMDAR1) is a therapeutic target for Gly-Hyp-Glu. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Gly-Hyp-Glu through regulating the expression of Glutamate receptor ionotropic NMDA 1 (NMDAR1). [1], [2]
References
Ref 1 Down-Regulation of m6A mRNA Methylation Is Involved in Dopaminergic Neuronal Death. ACS Chem Neurosci. 2019 May 15;10(5):2355-2363. doi: 10.1021/acschemneuro.8b00657. Epub 2019 Mar 14.
Ref 2 New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. doi: 10.1016/j.bmcl.2005.11.040.